Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications
Sarah J. Doran, Russell P. Sawyer
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Neuroprotective Effects of Dehydroepiandrosterone Sulphate Against Aβ Toxicity and Accumulation in Cellular and Animal Model of Alzheimer’s Disease
Barbara Vuić, Tina Milos, Erika Kvak, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 432-432
Open Access | Times Cited: 1
Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: a randomized controlled phase 2a trial
Brian G. Rash, Kevin Ramdas, Nataliya Agafonova, et al.
Nature Medicine (2025)
Open Access | Times Cited: 1
Approaches for Increasing Cerebral Efflux of Amyloid-β in Experimental Systems
David A. Loeffler
Journal of Alzheimer s Disease (2024) Vol. 100, Iss. 2, pp. 379-411
Open Access | Times Cited: 6
Engineering anti-amyloid antibodies with transferrin receptor targeting improves brain biodistribution and mitigates ARIA
Michelle E. Pizzo, Edward D. Plowey, Nathalie Khoury, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 5
Alzheimer’s drug with modest benefits wins backing of FDA advisers
Sara Reardon
Nature (2024)
Closed Access | Times Cited: 4
Clinical and research application of fluid biomarkers in autosomal dominant Alzheimer's disease and Down syndrome
María Carmona‐Iragui, Antoinette O’Connor, Jorge J. Llibre‐Guerra, et al.
EBioMedicine (2024), pp. 105327-105327
Open Access | Times Cited: 4
Mitochondrial Alterations, Oxidative Stress, and Therapeutic Implications in Alzheimer’s Disease: A Narrative Review
Erica Spina, Riccardo Rocco Ferrari, Elisa Pellegrini, et al.
Cells (2025) Vol. 14, Iss. 3, pp. 229-229
Open Access
Plasma Biomarkers for Cerebral Amyloid Angiopathy and Implications for Amyloid-Related Imaging Abnormalities: A Comprehensive Review
Mo‐Kyung Sin, Jeffrey L. Dage, Kwangsik Nho, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1070-1070
Open Access
ALZ‐801 prevents amyloid β‐protein assembly and reduces cytotoxicity: A preclinical experimental study
Daiki Muramatsu, Takahiro Watanabe‐Nakayama, Mayumi Tsuji, et al.
The FASEB Journal (2025) Vol. 39, Iss. 3
Open Access
A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system
Jingjing Huang, Xiaohong Long, Chunyong Chen
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Exploring the efficacy and safety of lecanemab in the management of early Alzheimer’s disease: A systematic review of clinical evidence
Rehab Emad Ashmawy, Olalekan John Okesanya, Bonaventure Michael Ukoaka, et al.
Journal of Alzheimer s Disease (2025)
Closed Access
Adverse events associated with lecanemab: A disproportionality analysis of data from the FDA adverse event reporting system
Jiahao Li, Feng Zhang, Ulrich Eisel
Journal of Alzheimer s Disease (2025)
Closed Access
Amyloid‐Related Imaging Abnormality (ARIA) Beyond the APOE‐ε4 Allele
Valentinus Besin, Farizky Martriano Humardani, Fenny Yudiarto, et al.
Chronic Diseases and Translational Medicine (2025)
Open Access
The potential and challenges of TREM2-targeted therapy in Alzheimer’s disease: insights from the INVOKE-2 study
Yanan Ma, Xiqi Hu, Kenji Karako, et al.
Frontiers in Aging Neuroscience (2025) Vol. 17
Open Access
Alzheimer’s Disease Immunotherapy and Mimetic Peptide Design for Drug Development: Mutation Screening, Molecular Dynamics, and a Quantum Biochemistry Approach Focusing on Aducanumab::Aβ2–7 Binding Affinity
Victor L. B. França, Eveline M. Bezerra, Roner F. da Costa, et al.
ACS Chemical Neuroscience (2024)
Open Access | Times Cited: 3
Amyloid-Directed Antibodies: Past, Present, and Future
Keith Noorda, Kevin Noorda, Marwan N. Sabbagh, et al.
Journal of Alzheimer s Disease (2024) Vol. 101, Iss. s1, pp. S3-S22
Closed Access | Times Cited: 3
The role of inflammation in neurological disorders: a brief overview of multiple sclerosis, Alzheimer’s, and Parkinson’s disease’
Yahveth Cantero‐Fortiz, Merçé Boada
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 3
Passive Anti-Amyloid Beta Immunotherapies in Alzheimer’s Disease: From Mechanisms to Therapeutic Impact
Thomas Gabriel Schreiner, Cristina Croitoru, Diana Nicoleta Hodorog, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1096-1096
Open Access | Times Cited: 2
The role of the FKBP51-Hsp90 complex in Alzheimer’s Disease: An emerging new drug target
Xavier Jeanne, Zsolt Török, László Vı́gh, et al.
Cell Stress and Chaperones (2024)
Open Access | Times Cited: 2
A case of severe ARIA with multiple infarctions and extensive microbleeds following lecanemab administration
Akiko Yamazaki, Tetsuro Sekine, Shirō Takahashi, et al.
Psychogeriatrics (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
Updated imaging markers in cerebral amyloid angiopathy: What radiologists need to know
Fumine Tanaka, M Maeda, Seiya Kishi, et al.
Japanese Journal of Radiology (2024)
Open Access | Times Cited: 2
Donanemab outperformed Aducanumab and Lecanemab on cognitive, but not on biomarker and safety outcomes: systematic review, frequentist and Bayesian network meta-analyses
Danko Jeremic, Juan D. Navarro‐López, Lydia Jiménez‐Díaz
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Prescribing Complexities: A Patient Story Related to Seizure History and the Changing Therapeutic Landscape of Alzheimer’s Disease
Mfon Umoh, Samuel W. Terman
Cureus (2024)
Open Access
Zerebrale Amyloidangiopathie
Robin Jansen, Solveig Henneicke, Sven G. Meuth, et al.
Neurologie up2date (2024) Vol. 07, Iss. 03, pp. 265-281
Closed Access
Volume and Permeability of White Matter Hyperintensity on Cognition: A DCE Imaging Study of an Older Cohort With and Without Cognitive Impairment
Changmok Lim, H. W. Lee, Yeonsil Moon, et al.
Journal of Magnetic Resonance Imaging (2024)
Open Access
Page 1 - Next Page

Scroll to top